{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T16:15:37Z","timestamp":1783008937399,"version":"3.54.5"},"reference-count":24,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2022,1,17]],"date-time":"2022-01-17T00:00:00Z","timestamp":1642377600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2022,4]]},"abstract":"<jats:p>Objective: This article summarizes the background, clinical trials, and place in therapy for the first two anti-CD19 monoclonal antibodies that have been recently FDA approved for patients with relapsed\/refractory (R\/R) diffuse large B-cell lymphoma (DLBCL). Summary: Treatment options are limited for patients that have relapsed after or are ineligible for autologous stem cell transplant (ASCT) or chimeric antigen receptor (CAR) T-cell therapy. Recent novel therapy approvals have started to change management strategies and outcomes for these patients. Two examples of recent FDA approvals are tafasitamab and loncastuximab tesirine, which represent the first anti-CD19 targeting monoclonal antibodies for patients with R\/R DLBCL. Tafasitamab was granted accelerated approval in combination with lenalidomide for adult patients with R\/R DLBCL after one or more lines of therapy based on the phase 2, L-MIND trial. Loncastuximab tesirine was granted accelerated approval for adult patients with R\/R DLBCL after two or more lines of therapy based on the phase 2, LOTIS-2 trial. The place in therapy and sequencing of these agents can present a challenge to prescribers especially in regards to patients being evaluated for CD19 targeting CAR T-cell therapy. Conclusion: Tafasitamab and loncastuximab tesirine are options for use in patients with R\/R DLBCL and are welcome additions to the limited therapy options for these patients. Further data is needed to elucidate sequencing and the impact these agents may have on CAR T-cell therapy. Ongoing clinical trials are studying these agents in the upfront setting in combination with other chemoimmunotherapy agents which may further expand treatment options for patients with B-cell lymphomas.<\/jats:p>","DOI":"10.1177\/10781552211073575","type":"journal-article","created":{"date-parts":[[2022,1,17]],"date-time":"2022-01-17T08:47:37Z","timestamp":1642409257000},"page":"686-690","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":11,"title":["Newly approved anti-CD19 monoclonal antibodies for the treatment of relapsed or refractory diffuse large  B-cell lymphoma"],"prefix":"10.1177","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7978-1652","authenticated-orcid":false,"given":"James A.","family":"Davis","sequence":"first","affiliation":[{"name":"Clinical Pharmacy Specialist \u2013 Malignant Hematology, MUSC Hollings Cancer Center, Charleston, SC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8479-1430","authenticated-orcid":false,"given":"Abigail","family":"Shockley","sequence":"additional","affiliation":[{"name":"PGY2 Oncology Pharmacy Resident, MUSC College of Pharmacy, Charleston, SC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley E.","family":"Glode","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, CO, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2022,1,17]]},"reference":[{"key":"bibr1-10781552211073575","unstructured":"National Comprehensive Cancer Network. B-cell lymphomas (version 4.2021), https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/b-cell.pdf (accessed 16 September 2021)."},{"key":"bibr2-10781552211073575","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2027612"},{"key":"bibr3-10781552211073575","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00014"},{"key":"bibr4-10781552211073575","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00191-1"},{"key":"bibr5-10781552211073575","unstructured":"FDA. Hematology\/oncology (cancer) approvals & safety notifications, www.fda.gov\/drugs\/resources-information-approved-drugs\/hematologyoncology-cancer-approvals-safety-notifications (accessed 18 September 2021)."},{"key":"bibr6-10781552211073575","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30225-4"},{"key":"bibr7-10781552211073575","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.5363"},{"key":"bibr8-10781552211073575","volume-title":"Lexi-drugs online [database on the internet]","author":"Tafasitmab","year":"2021"},{"key":"bibr9-10781552211073575","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00139-X"},{"key":"bibr10-10781552211073575","volume-title":"Zynlonta (loncastuximab tesirine) injection [package insert]","year":"2021"},{"key":"bibr11-10781552211073575","volume-title":"Lexi-drugs online [database on the internet]","year":"2021"},{"key":"bibr12-10781552211073575","unstructured":"Home - ClinicalTrials.gov, https:\/\/clinicaltrials.gov\/ (accessed 19 September 2021)."},{"key":"bibr13-10781552211073575","unstructured":"MorphoSys AG. A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab Plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients With newly-diagnosed diffuse large B-cell lymphoma (DLBCL). Clinical Trial Registration NCT04824092, clinicaltrials.gov, https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04824092 (25 May 2021, accessed 16 September 2021)."},{"key":"bibr14-10781552211073575","unstructured":"MorphoSys AG. A phase 2\/3, randomised, multicentre study of tafasitamab With bendamustine versus rituximab With bendamustine in patients With relapsed or refractory diffuse large B-cell lymphoma (R-R DLBCL) Who Are Not eligible for high-dose chemotherapy (HDC) and autologous stem-cell transplantation (ASCT). Clinical Trial Registration NCT02763319, clinicaltrials.gov, https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02763319 (9 June 2021, accessed 16 September 2021)."},{"key":"bibr15-10781552211073575","unstructured":"Incyte Corporation. A phase 3, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of tafasitamab Plus lenalidomide in addition to rituximab versus lenalidomide in addition to rituximab in patients With relapsed\/refractory (R\/R) follicular lymphoma grade 1 to 3a or R\/R marginal zone lymphoma. Clinical Trial Registration NCT04680052, clinicaltrials.gov, https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04680052 (10 August 2021, accessed 16 September 2021)."},{"key":"bibr16-10781552211073575","unstructured":"MorphoSys AG. A phase II, Two-cohort, open-label, multicenter study to evaluate the safety and preliminary efficacy of MOR00208 combined With idelalisib or venetoclax in patients With relapsed or refractory CLL\/SLL previously treated With bruton\u2019s tyrosine kinase (BTK) inhibitor. Clinical Trial Registration NCT02639910, clinicaltrials.gov, https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02639910 (20 January 2020, accessed 16 September 2021)."},{"key":"bibr17-10781552211073575","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25591"},{"key":"bibr18-10781552211073575","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0564-6"},{"key":"bibr19-10781552211073575","unstructured":"ADC Therapeutics S.A. A phase 2 randomized study of loncastuximab tesirine versus idelalisib in patients With relapsed or refractory follicular lymphoma (LOTIS 6). Clinical Trial Registration NCT04699461, clinicaltrials.gov, https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04699461 (2 August 2021, accessed 16 September 2021)."},{"key":"bibr20-10781552211073575","unstructured":"ADC Therapeutics S.A. A phase 3 randomized study of loncastuximab tesirine combined With rituximab versus immunochemotherapy in patients With relapsed or refractory diffuse large B-cell lymphoma (DLBCL) (LOTIS-5). Clinical Trial Registration NCT04384484, clinicaltrials.gov, https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04384484 (20 August 2021, accessed 16 September 2021)."},{"key":"bibr21-10781552211073575","unstructured":"ADC Therapeutics S.A. A phase 1\/2 open-label study to evaluate the safety and efficacy of loncastuximab tesirine and ibrutinib in patients With advanced diffuse large B-cell lymphoma or mantle cell lymphoma (LOTIS-3). Clinical Trial Registration NCT03684694, clinicaltrials.gov, https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03684694 (26 April 2021, accessed 16 September 2021)."},{"key":"bibr22-10781552211073575","unstructured":"MD JPA. Phase 2, single-arm, open-label, study of loncastuximab tesirine in combination With rituximab in patients With relapsed or refractory follicular lymphoma. Clinical Trial Registration NCT04998669, clinicaltrials.gov, https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04998669 (7 August 2021, accessed 16 September 2021)."},{"key":"bibr23-10781552211073575","unstructured":"ADC Therapeutics S.A. A phase 1b open-label study to evaluate the safety and anti-cancer activity of loncastuximab tesirine in combination With other anti-cancer agents in patients With relapsed or refractory B-cell Non-hodgkin lymphoma (LOTIS 7). Clinical Trial Registration NCT04970901, clinicaltrials.gov, https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04970901 (10 September 2021, accessed 16 September 2021)."},{"key":"bibr24-10781552211073575","unstructured":"ADC Therapeutics S.A. A phase 1b, open-label, study to evaluate the tolerability, safety, pharmacokinetics, and antitumor activity of loncastuximab tesirine in combination With R-CHOP in patients With previously untreated diffuse large B-cell lymphoma (LOTIS-8). Clinical Trial Registration NCT04974996, clinicaltrials.gov, https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04974996 (22 July 2021, accessed 16 September 2021).n"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552211073575","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552211073575","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552211073575","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:25:58Z","timestamp":1777688758000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552211073575"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,17]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["10.1177\/10781552211073575"],"URL":"https:\/\/doi.org\/10.1177\/10781552211073575","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,17]]}}}